Objectives To describe low-density lipoprotein (LDL) cholesterol management and lipid-lowering treatment patterns in patients with a cardiovascular (CV) event. Design Retrospective cohort study using Clinical Practice Research Datalink records linked with Hospital Episode Statistics data. Setting Routine clinical practice in the UK from 2006 to 2012. Participants Individuals ≥18 years were selected at their first CV-related hospitalisation (first event cohort) if they had received ≥2 lipid-lowering therapy prescriptions within 180 days beforehand. Patients were stratified into four mutually exclusive subgroups based on the presence or absence of vascular disease and of diabetes. Those with a second CV hospitalisation within 36 months were i...
Objective: To assess hospital prescribing of lipid-lowering agents in a tertiary hospital, and exami...
Objective:To assess low-density lipoprotein cholesterol (LDL-C) response in patients after initiatio...
Aims To analyse the treatment and control of dyslipidaemia in patients at high and very high cardio...
OBJECTIVES: To describe low-density lipoprotein (LDL) cholesterol management and lipid-lowering trea...
<p><b>Objective:</b> To assess the prevalence of patients at very high risk of cardiovascular (CV) e...
Objective: Since dyslipidaemia is one of the most important risk factors for coronary heart disease ...
International audienceBACKGROUND: LDL-cholesterol therapeutic objectives attainment under lipid lowe...
Guidelines developed by the American College of Cardiology/American Heart Association (ACC/AHA) reco...
International audienceAims:To improve attainment of LDL-cholesterol (LDL-c) targets, an expert group...
Introduction: Since 2011, the European guidelines have included a specific low-density lipoprotein c...
Background: In 2014, guidelines from the National Institute for Health and Care Excellence (NICE) pr...
ObjectivesThis study sought to determine if an aggressive, focused low-density lipoprotein cholester...
Objectives. The aim of this study was to assess treatment patterns of lipid-lowering therapy (LLT) i...
none10siPurpose: Current European guidelines recommend that patients free from cardiovascular diseas...
Background: Clinical guidelines recommend specific targets for low-density lipoprotein cholesterol (...
Objective: To assess hospital prescribing of lipid-lowering agents in a tertiary hospital, and exami...
Objective:To assess low-density lipoprotein cholesterol (LDL-C) response in patients after initiatio...
Aims To analyse the treatment and control of dyslipidaemia in patients at high and very high cardio...
OBJECTIVES: To describe low-density lipoprotein (LDL) cholesterol management and lipid-lowering trea...
<p><b>Objective:</b> To assess the prevalence of patients at very high risk of cardiovascular (CV) e...
Objective: Since dyslipidaemia is one of the most important risk factors for coronary heart disease ...
International audienceBACKGROUND: LDL-cholesterol therapeutic objectives attainment under lipid lowe...
Guidelines developed by the American College of Cardiology/American Heart Association (ACC/AHA) reco...
International audienceAims:To improve attainment of LDL-cholesterol (LDL-c) targets, an expert group...
Introduction: Since 2011, the European guidelines have included a specific low-density lipoprotein c...
Background: In 2014, guidelines from the National Institute for Health and Care Excellence (NICE) pr...
ObjectivesThis study sought to determine if an aggressive, focused low-density lipoprotein cholester...
Objectives. The aim of this study was to assess treatment patterns of lipid-lowering therapy (LLT) i...
none10siPurpose: Current European guidelines recommend that patients free from cardiovascular diseas...
Background: Clinical guidelines recommend specific targets for low-density lipoprotein cholesterol (...
Objective: To assess hospital prescribing of lipid-lowering agents in a tertiary hospital, and exami...
Objective:To assess low-density lipoprotein cholesterol (LDL-C) response in patients after initiatio...
Aims To analyse the treatment and control of dyslipidaemia in patients at high and very high cardio...